The I-SPY2 trial reported a significantly enhanced pathologic complete response when durvalumab and olaparib were combined with paclitaxel in comparison with chemotherapy alone among women with stage II/III high-risk, HER2-negative BC; improvement was observed in both the HR+ and TNBC subsets [146]. Here, ERBB2 is linked to breast cancer.